Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Urinary Bladder Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 9Neoplasms 8Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 6Neoplasm Metastasis 6Lung Neoplasms 6Colorectal Neoplasms 5Ovarian Neoplasms 4Lymphoma, Follicular 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Cholangiocarcinoma 3Brain Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

paclitaxel poliglumex 1nazartinib 1atezolizumab 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Non-small Cell Lung Cancer × atezolizumab × Clear all
NCT03014648 2023-12-13

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

University of Pittsburgh

Phase 2 Completed
28 enrolled 22 charts
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡